NCT00000327

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2)

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 62 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF) buprenorphine/naloxone combination tablet administration and determine whether outcomes are improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one in which take-home doses are given on intervening days.

Detailed description

Mon/Wed/Fri dosing with the 8 mg buprenorphine/naloxone tablet is as safe and effective as daily dosing and is preferred by patients to daily dosing. Multiple doses of the combination tablet (e.g. 16mg, 24mg) are well tolerated by patients. A 3 day schedule with take-outs is as effective as a 3-day schedule in which all medication is ingested at the clinic

Conditions

• Heroin Dependence
• Opioid-Related Disorders

Interventions

Type	Name	Description
DRUG	Heroin Dependence

Timeline

• Start date: 1997-06-01
• Primary completion: 1997-08-01
• Completion: 1997-08-01
• First posted: 1999-09-21
• Last updated: 2017-05-04

Locations

1 site across 1 country: United States